MedAssets, Inc. (MDAS) - NASDAQ
  • Nov. 2, 2015, 12:48 PM
    | Nov. 2, 2015, 12:48 PM | 23 Comments
  • Nov. 2, 2015, 8:23 AM
    • Pamplona Capital Management acquires MedAssets (NASDAQ:MDAS) for $31.35 per share in cash or ~$2.7B. Pamplona partner Jeremy Gelber, M.D., says, "We are excited to be acquiring this leading healthcare performance improvement platform company that serves four out every five hospitals in the U.S. As a next step to our strategy, we plan to combine the MedAssets Revenue Cycle Management (RCM) segment with our Precyse business to create a leading, end-to-end revenue cycle technology and services business. At the same time, we intend to sell the MedAssets Spend and Clinical resource Management (SCM) business to VHA-UHC Alliance. In each case, we believe these business combinations will enable greater innovation and scale to deliver enhanced clinical, operational and financial performance improvement to positively impact healthcare organizations' outcomes."
    • The financial terms of the sales to VHA-UHC are not disclosed. The transaction should close in early 2016.
    | Nov. 2, 2015, 8:23 AM
  • Aug. 4, 2015, 9:20 AM
    | Aug. 4, 2015, 9:20 AM | 1 Comment
  • Aug. 3, 2015, 6:02 PM
    • Activist Starboard Value, which has called for and obtained big changes at many companies, has disclosed a 5.22M-share (8.7%) stake in MedAssets (NASDAQ:MDAS). (13D filing)
    • Starboard has sent an open letter (.pdf) to CEO R. Halsey Wise and MedAssets' board. From the 13D: "In the letter, Starboard expressed its belief, among other things, that the Issuer is deeply undervalued relative to the quality of its assets and the earnings power of its core business.  Starboard also outlined in the letter a plan to create significant shareholder value by reducing the Issuer’s operating expenses, improving capital allocation, improving corporate governance and exploring all available strategic alternatives ... Starboard also expressed its belief in the letter that if the Issuer were to pursue Starboard’s plan of action, the stock price of the Issuer could be $37-$46 by the end of 2016."
    • The healthcare software/services provider has jumped to $26.99 in AH trading.
    | Aug. 3, 2015, 6:02 PM
  • Jun. 18, 2015, 5:36 PM
    | Jun. 18, 2015, 5:36 PM | 4 Comments
  • Feb. 18, 2015, 12:51 PM
    | Feb. 18, 2015, 12:51 PM
  • Feb. 18, 2015, 9:15 AM
    | Feb. 18, 2015, 9:15 AM
  • Feb. 18, 2015, 8:42 AM
    • MedAssets (NASDAQ:MDAS) is off 15% premarket on higher-than-normal volume in response to its fiscal year EPS guidance of $1.13 - 1.23, lower than consensus of $1.45. Revenue forecast of $753M - 767M is in-line with consensus of $758M.
    | Feb. 18, 2015, 8:42 AM
  • Jul. 16, 2013, 3:39 PM

    Demand for MedAssets' (MDAS +3.7%) "capabilities will grow as healthcare reform progresses," Jefferies says, initiating the "cheap" shares at Buy and setting a $23 price target. The company's "comprehensive and innovative suite of solutions" should be valuable for hospitals coping with a variety of challenges. Analyst Sean Dodge sees long-term revenue growth of 8%+ and adjusted EPS growth of 13-14% going forward.

    | Jul. 16, 2013, 3:39 PM
  • May 1, 2013, 5:46 PM
    MedAssets (MDAS): Q1 EPS of $0.41 beats by $0.11. Revenue of $172.8M (+15.3% Y/Y) beats by $8.06M. Shares +4.8% AH. (PR)
    | May 1, 2013, 5:46 PM
  • Feb. 21, 2013, 5:43 PM
    After-hours top gainers, as of 5:15 p.m.: ARUN +14%. WBMD +14%. ACTG +13%. FIRE +11%. BLOX +10%.
    After-hours top losers: IMMU -7%. MDAS -6%. VVR -3%. VVUS -3%. PEGA -3%.
    | Feb. 21, 2013, 5:43 PM
  • Aug. 2, 2012, 3:38 PM
    Shares of MedAssets (MDAS +19.8%) power forward against a weak tape after easily beating on its Q2 top and bottom line. The company also raised guidance, now seeing its FY12 EPS between $1.05 - $1.13 on revenue of around $620M - $630M. Street estimates are for an EPS of $1.06 on revenue of $608M. Raymond James ups the shares to Strong Buy on the back of the strong result.
    | Aug. 2, 2012, 3:38 PM
  • Jun. 21, 2012, 11:55 AM

    MedAssets (MDAS +1.8%) moves up on an upgrade to Buy at UBS, saying the company's RCM segment growth will accelerate, and when combined with SCM execution it should drive shares higher. The firm raises its price target to $18 from $14.

    | Jun. 21, 2012, 11:55 AM
  • Feb. 14, 2012, 9:16 AM

    MedAssets (MDAS+16.3% premarket on takeover speculation after DealReporter cites sources saying the company has hired J.P. Morgan to explore a leveraged buyout.

    | Feb. 14, 2012, 9:16 AM
  • Jan. 9, 2012, 11:23 AM
    Tremblant Capital discloses a stake (13G) in SodaStream (MDAS -1.4%) of 9.79%, marking the first time it revealed an ownership position in the beverage carbonation systems manufacturer.
    | Jan. 9, 2012, 11:23 AM
  • Nov. 4, 2011, 2:44 PM

    MedAssets (MDAS +19%) pops after its Q3 shreds Street EPS estimates. Net revenue rose 50% Y/Y, primarily due to a lower tax rate and write-downs related to its 2010 acquisition of Broadlane. Oppenheimer and Morgan Stanley both issue positive comments after the results, reiterating their Outperform and Overwieght ratings on the shares (I, II).

    | Nov. 4, 2011, 2:44 PM
Company Description
MedAssets Inc is a healthcare performance improvement company. It provides technology-enabled products & services helping customers in healthcare organizations, including hospitals, health systems, payers, other service providers & product manufacturers.
Sector: Technology
Industry: Healthcare Information Services
Country: United States